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S U M M A R Y
Objectives: The objectives of this study were to analyze the association between the classiﬁcation of
toxoplasmosis in the pregnant woman (TP) according to the classiﬁcation of Lebech et al. and the
incidence of congenital toxoplasmosis (CT), also taking into consideration prenatal treatment.
Methods: A clinical cohort study of 524 children followed-up until 1 year of age was conducted. Adjusted
odds ratios (OR) were estimated by logistic regression.
Results: Of 519 pregnant women, 61.3% were not classiﬁed due to the incompleteness of hospital
records. Among the pregnant women classiﬁed as conﬁrmed cases of TP (n = 19), the CT risk was six
times greater than in the probable/possible group. No case of CT was identiﬁed in the group of pregnant
women classiﬁed as unlikely to have TP. The children with no prenatal treatment (46.2% n = 242/524)
presented a risk almost three times greater of CT than the treated children (OR 2.77, 95% conﬁdence
interval (CI) 1.54–4.97; p = 0.001). Complete prenatal treatment was identiﬁed as a protecting factor for
CT (OR 0.35, 95% CI 0.19–0.65; p = 0.001).
Conclusions: A lack or incomplete prenatal treatment was identiﬁed as an important risk factor for CT in
this study. The proportions of non-classiﬁed mothers and children with no prenatal treatment reﬂect the
need to improve prenatal care in Brazil.
 2012 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
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Congenital toxoplasmosis (CT) can cause serious neurological
and ocular sequelae, even among asymptomatic children. CT is a
preventable and treatable infection,1–4 and the identiﬁcation of
risk factors for transmission during pregnancy may help in the
clinical management of suspected children. Well known risk
factors are acute toxoplasmosis in pregnancy (TP) and the timing of
occurrence (the later the appearance of the infection, the greater
the chance of transmission).5,6 Considering that 90% of women
with TP are asymptomatic, the diagnosis of TP is based on the
results of serological tests.
In Brazil, TP and CT screening is performed on an irregular basis,
as there is limited access to laboratory tests. Although there are no
guidelines from the Health Ministry, the clinical control of CT in the
Federal District (FD) is guided by the Manual of gestational and
congenital toxoplasmosis.7 However, even in the FD the diagnosis of
TP is difﬁcult, particularly the systematic testing of IgG and IgA,
and avidity testing for IgG antibodies. Thus, the diagnosis of TP is* Corresponding author. Tel.: +55 61 78113957.
E-mail address: liucampp@gmail.com (L. Campello Porto).
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http://dx.doi.org/10.1016/j.ijid.2012.01.016usually based on accessible tests (IgG and IgM), the results of
which are not always conclusive in relation to the occurrence of
infection.
Lebech et al. correlated various serological proﬁles to the
probability of TP, classifying pregnant women as having either a
conﬁrmed or presumed (probable, possible, or unlikely) infec-
tion.8 Because this classiﬁcation is possible regardless of the
systematic testing for IgG and IgA and avidity testing for IgG, it
was considered to be more suitable for the present study.
However, studies assessing the association between the classiﬁ-
cation of TP according to Lebech et al. and the occurrence of CT
were not identiﬁed in the reviewed literature. There is also
controversy regarding the role of prenatal treatment in reducing
vertical transmission.9–17
Therefore, the objective of this study was to analyze the
associations between the classiﬁcation of TP and the risk of CT, and
prenatal treatment and the risk of CT, in a clinical cohort of children
identiﬁed during 15 years and followed-up until the age of 1 year at
a reference service for CT in the FD. These results may help
obstetricians and pediatricians in the appropriate diagnosis and
treatment of pregnant women and children who are suspected to
have CT, in relation to laboratory investigations and therapeutic
interventions.ternational Society for Infectious Diseases.
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2.1. Study population
Eligible children (n = 533) were those whose mothers were
considered suspected or deﬁnite cases of TP. All of the mothers had
positive IgG tests. These mothers were referred to the pediatric
infectious diseases unit of the Regional Hospital of Asa Sul (PID-
HRAS) by their babies’ pediatricians based on prenatal data regarding
their serologic status (positive IgG). All mothers and babies referred
to PID-HRAS were identiﬁed during the period from May l994 to
October 2009 at the pediatric infectious diseases outpatient unit.
This is the only referral service for the investigation, follow-up, and
treatment of CT of the State Health Secretariat, FD. Of the 533 eligible
children, nine were lost to clinical follow-up before diagnosis.
The diagnosis of CT was conﬁrmed by the persistence of IgG
antibodies up to 12 months of life. All of the children were examined
at birth and underwent clinical follow-up performed by the
infectious diseases specialist and ophthalmologist and laboratory
testing starting within the ﬁrst 3 months of life. Laboratory
investigations were repeated according to the clinical criteria, and
included complete speciﬁc serological tests, hemogram, radiology
exams (X-ray of the skull and ultrasonogram (US) and computed
axial tomography (CAT) scan of the brain), and study of the
cerebrospinal ﬂuid (CSF). Serological testing was repeated at 1, 3, 5,
8, and 12 months, or until IgG antibodies were negative.
The mothers of the eligible children were classiﬁed into ﬁve
groups according to the probability of TP, using the classiﬁcation of
Lebech et al.,8 modiﬁed by the authors, as follows: (1) Deﬁnite:
seroconversion – both samples taken after conception; positive
culture from maternal blood; conﬁrmed congenital infection in
offspring. (2) Probable: seroconversion – ﬁrst sample taken within
2 months before conception; signiﬁcant rise of IgG titers, and
presence of IgM and/or IgA; high IgG titers, presence of IgM and/or
IgA and onset of lymphadenopathy during pregnancy; high IgG
titers and presence of IgM and/or IgA in the second half of
pregnancy. (3) Possible: stable high IgG, without IgM, in the second
half of pregnancy; high IgG and the presence of IgM and/or IgA in
the ﬁrst half of pregnancy. (4) Unlikely: stable low IgG, with or
without IgM; stable high IgG, without IgM, in early pregnancy. (5)
Not classiﬁed: non-quantiﬁed IgG antibody results.
The authors modiﬁed the classiﬁcation of Lebech et al. by
excluding the ﬁfth group (‘not infected’) and creating a new group
‘not classiﬁed’ to prevent the exclusion of a large number of
mothers. The ‘not infected’ group was deﬁned by Lebech et al. as:
seronegative (during pregnancy); maternal preconception sero-
positive sample; positive IgM and/or IgA without the appearance of
IgG. This group was excluded by the authors because all eligible
children were born from a mother suspected of TP.
Prenatal treatment aims to prevent transplacental transmission
of Toxoplasma gondii and to treat fetuses that are possibly infected.
The therapeutic regimens studied were: (1) spiramycin (2 tablets
every 12 h) for 21 days; (2) pyrimethamine (2 tablets once a day, at
the same time) associated with sulfadiazine (2 tablets every 6 h)
and with folinic acid (1 tablet three times a week); (3) regimens 1
and 2 alternately every 21 days.
Other variables related to treatment that were analyzed were
the trimester in which treatment was initiated and the duration of
treatment. Treatment was considered continuous when given until
delivery.
2.2. Study design
This historical cohort study was based on medical records of
clinical and laboratory data related to pregnancy and the follow-up
of the children.2.3. Data analysis
Data analysis included descriptive and analytic stages. In the
descriptive stage, the incidence of CT was studied for each group of
pregnant women classiﬁed according to the classiﬁcation of Lebech
et al.8 Prenatal treatment data were described with the correspond-
ing 95% conﬁdence intervals (95% CI) based on the exact method.
In the analytic stage, associations between the selected
explanatory variables (classiﬁcation of TP according to the
classiﬁcation of Lebech et al.8 and data on prenatal treatment)
and CT were estimated using logistic regression models. Crude and
adjusted odds ratios (OR) were estimated along with their
respective 95% CI. For the statistical signiﬁcance of the hypothesis
tests, the accepted type 1 error was 5%. Stata software (version 10)
was used for all the analyses.18
The research protocol conforms to Brazilian Resolution No. 196/
96 concerning ethical aspects of research on human beings. The
study was approved and authorized by the director of the Regional
Hospital of Asa Sul and by the Research Ethics Committee of the
State Health Secretariat, FD.
3. Results
Among 519 mothers analyzed (n = 5 mothers of twins) it was
not possible to classify 318 (61.3%) of them according to the
classiﬁcation of Lebech et al.8 due to incomplete information about
serological tests (Table 1). Nineteen (3.7%) mothers were classiﬁed
as deﬁnite, 111 (21.4%) as probable, 46 (8.9%) as possible, and 25
(4.8%) as unlikely cases of TP.
Overall, the incidence of CT in this study was 11.3% (n = 524).
The CT incidence was larger for pregnant women classiﬁed as
deﬁnite cases (42.1%, 95% CI 19.90–64.31%) compared to the other
groups of mothers classiﬁed as probable cases (10.8%, 95% CI 5.03–
16.59%) and possible cases (19.6%, 95% CI 8.10–31.03%) of CT. For
these latter two groups, the classiﬁcation of Lebech et al.8 had
limited discriminatory power to identify CT. In contrast, there were
no CT cases among mothers classiﬁed as unlikely cases of TP.
Children whose mothers were listed as deﬁnite cases of TP
(n = 19) had a risk almost four times greater of having CT than
those born to mothers listed as presumed cases (n = 182). In the
ﬁrst group, 63.2% (n = 12/19) received speciﬁc prenatal treatment
during pregnancy, and in the second group, 55.5% (n = 101/182)
received such treatment (data not presented).
Among children treated during the prenatal period, the
probability of CT was 6.7% (95% CI 3.81–9.66%) in contrast to
the group that was not treated, in which the probability rose to
16.7% (95% CI 11.76–21.57%). Thus, children who were not treated
during the prenatal period showed a risk 2.8 (95% CI 1.54–4.97)
times greater of been a CT case than those who were treated.
The risk of CT among untreated children and those who had no
record of receiving prenatal treatment was rather similar,
indicating that in this latter group, the majority of children were
probably untreated during the prenatal stage (Table 1).
Among the 19 pregnant women listed as deﬁnite cases of TP, 12
were treated, six were not, and one had no information regarding
treatment (data not presented). The transmission rate of CT in the
group of deﬁnite cases when treated was 41.7% (n = 5/12) and
when untreated was 33.3% (n = 2/6). The rates of CT transmission
were even lower among probable, possible, and unlikely cases
(n = 182) when untreated (17.3%, n = 14/81) or when treated
prenatally (6.0%, n = 6/101) (data not presented).
The rate of CT among children whose mothers were given
regimen 1 of prenatal treatment (spiramycin; n = 210) was 8.1%
(95% CI 4.41–11.78%). This rate decreased to 2.9% (95% CI 0–8.38%)
among children whose mothers received regimen 2 (n = 35) and to
0% among children whose mothers were given regimen 3 (n = 18).
Table 1
Classiﬁcation of the probability of toxoplasmosis infection in pregnancy (TP) and prenatal treatment among mothers (n = 519) of eligible children from the pediatric infectious
diseases unit of the Regional Hospital of Asa Sul, Brasilia, May 1994–October 2009
Variables Cases n % 95% Conﬁdence interval
Classiﬁcation of Lebech et al. (n = 519 mothers)
Deﬁnite 8 19 42.1 19.90–64.31
Probable 12 111 10.8 5.03–16.59
Possible 9 46 19.6 8.10–31.03
Unlikely 0 25 0 -
Not classiﬁed 30 318 9.4 6.22–12.65
Prenatal treatment (n = 524 children)
Yes 19 282 6.7 3.81–9.66
No 37 222 16.7 11.76–21.57
Not informed 3 20 15 0.00–30.65
Therapeutic regimensa (n = 524 children)
Regimen 1 17 210 8.1 4.41–11.78
Regimen 2 1 35 2.9 0.00–8.38
Regimen 3 0 18 0 -
No information about the regimen 1 19 5.3 0.00–15.30
Not treated or not informed 40 242 16.5 11.85–21.21
Time of treatment (n = 524 children)
First trimester 3 95 3.2 0.00–6.67
Second trimester 7 107 6.5 1.86–11.23
Third trimester 9 80 11.3 4.33–18.17
Not treated or not informed 40 242 16.5 11.85–21.21
Duration of treatmentb (n = 524 children)
Continuous 15 243 6.2 3.15–9.20
Interrupted 4 39 10.3 0.73–19.78
Not treated or not informed 40 242 16.5 11.85–21.21
Total 59 524 11.3 7.57–14.95
a Regimen 1 = spiramycin; regimen 2 = pyrimethamine + sulfadiazine + folinic acid; regimen 3 = regimens 1 and 2 alternately every 21 days.
b Continuous = treatment compliance until the end of pregnancy; Interrupted = treatment interrupted before birth.
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with no information regarding the drugs, showed a rate of 5.3%
(95% CI 0.0–15.30%) of CT (Table 1).
Among 95 children who had treatment initiation in the ﬁrst
trimester of pregnancy, the rate of CT was 3.2% (95% CI 0–6.67%).
The rate of CT increased for those children whose mother started
treatment during the other two trimesters of pregnancy: 6.5% (95%
CI 1.86–11.23%) when initiated in the second trimester and 11.3%
(95% CI 4.33–18.17%) when initiated in the third.Table 2
Estimates of the association between congenital toxoplasmosis and selected variables (b
diseases unit of the Regional Hospital of Asa Sul, Brasilia, May 1994–October 2009
Variable Unadjusted regress
Crude OR 95% C
Category of infection 
Deﬁnite 6.65 2.47–
Probable 1.08 0.53–
Possible 2.22 0.97–
Unlikely/not classiﬁed (ref.)
Prenatal treatment 
Yes (ref.)
No 2.77 1.54–
No information 2.44 0.66–
Type of treatment 
Regimen 1 (ref.)
Regimen 2 or 3 0.22 0.03–
No information about the regimen 0.63 0.08–
No treatment (+20 children with no treatment information) 2.25 1.23–
Time of treatment 
First trimester (ref.)
Second trimester 2.15 0.54–
Third trimester 3.89 1.02–
No treatment/no information 6.07 1.83–
Duration of treatment 
Continuous 0.35 0.19–
Other (ref.)
OR, odds ratios; 95% CI, 95% conﬁdence intervals.
a Variables adjusted for classiﬁcation of Lebech et al.The prenatal treatment was considered continuous for the
majority of children (n = 243), and the CT rate in this group was
6.2% (95% CI 3.15–9.20%). Among children whose treatment was
interrupted before birth (n = 39), the CT rate increased to 10.3%
(95% CI 0.73–19.78%).
The results of logistic regression for the associations of CT rate
and the classiﬁcation of TP (according to Lebech et al.8modiﬁed by
the authors), and CT rate and prenatal treatment, are given in
Table 2.ased on logistic regression analysis) among children seen at the pediatric infectious
ion model Adjusted regression modela
I p-Value Adjusted OR 95% CI p-Value Overall p-Value
0.002
17.91 <0.001 9.59 3.41–26.94 <0.001
2.20 0.841 1.51 0.73–3.17 0.267
5.08 0.058 1.97 0.85–4.56 1.112
0.002
4.97 0.001 3.01 1.61–5.64 0.001
9.08 0.182 2.68 0.68–10.56 0.159
0.005
1.68 0.144 0.19 0.02–1.51 0.115
5.02 0.663 0.43 0.05–3.76 0.444
4.10 0.008 2.36 1.24–4.46 0.008
0.004
8.55 0.279 2.13 0.52–8.67 0.291
14.89 0.048 3.34 0.85–13.17 0.085
20.14 0.003 6.24 1.83–21.22 0.003
0.001
0.65 0.001 0.33 0.17–0.64 0.001
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tion of TP and CT indicated that among deﬁnite cases of TP the rate
of CT was six times greater (OR 6.65, 95% CI 2.47–17.91; p < 0.001)
than among unlikely or not classiﬁed cases of TP. The probability of
CT among probable (OR 1.08, 95% CI 0.53–2.20; p = 0.84) and
possible (OR 2.22, 95% CI 0.97–5.08; p = 0.058) cases of TP were
similar to the reference group (unlikely or not classiﬁed cases of
TP). A similar result was obtained when results were adjusted for
prenatal treatment, except for the enhancement of the magnitude
of association between deﬁnite cases of TP and CT: the rate of CT
was 9.6 times greater among deﬁnite cases of TP than in unlikely or
non-classiﬁed cases of TP (reference group).
In the univariate analysis, the lack of prenatal treatment was
statistically associated with the CT rate, which remained even after
controlling for classiﬁcation of TP. Children who did not receive
prenatal treatment had a three times greater chance of CT (OR 3.01,
95% CI 1.61–5.64; p = 0.001) than children who were treated
prenatally. The treatment regimen did not appear to have any
inﬂuence on the CT rate (regimen 2 or 3 vs. regimen 1: OR 0.19;
p = 0.115).
When the association between the time of prenatal treatment
initiation and CT (adjusting by classiﬁcation of TP) was analyzed,
an increasing trend in the CT rate was observed. When compared to
children treated since the ﬁrst trimester, the chance of CT in the
group that was treated since the second trimester was two times
greater (OR 2.13, 95% CI 0.52–8.67; p = 0.291), and since the third
trimester it was three times greater (OR 3.34, 95% CI 0.85–13.17;
p = 0.085). Children who were not treated during the prenatal
period had a six times greater chance (OR 6.24, 95% CI 1.83–21.22;
p = 0.003) of CT compared to those who were treated since the ﬁrst
trimester, even after adjusting by classiﬁcation of TP. It is worth
mentioning that, overall, this gradient resulted in a statistically
signiﬁcant association (p = 0.004), yet only the category of the
untreated children presented a signiﬁcant p-value (p = 0.008).
Treatment compliance until the end of pregnancy (continuous
treatment), was identiﬁed as a protective factor: children with
continuous treatment presented only 33% (OR 0.33, 95% CI 0.17–
0.64; p = 0.001) of the chance of conﬁrmation of CT compared to
those children who did not receive prenatal treatment or for whom
treatment was interrupted before birth.
4. Discussion
The children born to mothers listed as deﬁnite cases of TP
(according to the criteria of Lebech et al.,8 modiﬁed by the authors)
had a greater chance of CT compared to the group of children born
to mothers listed as unlikely or not classiﬁed cases of TP. In
addition, less chance of CT was observed among children who
received speciﬁc continuous prenatal treatment and for whom this
was initiated during the ﬁrst trimester of pregnancy (in contrast to
reference groups).
The overall CT rate in the study population was 11.3%. Most
studies on CT refer to the incidence observed in the general
population of live-birth babies, regardless of their mothers’
serology status. As expected, the CT incidence in such settings is
much lower than that observed in our study,19–22 in which all
mothers had been referred to our service because they were
considered suspected of TP.
Among women listed as deﬁnite cases, the CT rate was 42.1%.
Similar rates have been described by the Argentine Consensus on
Congenital Toxoplasmosis23 and by Lebech et al.,8 who estimated
40% for the overall CT rate.
In contrast to the deﬁnite cases of TP, transmission rates of CT
were considered less signiﬁcant in the groups of women listed as
probable (10.8%) and possible (19.6%) cases. There were no cases
among women listed as unlikely to have infection in pregnancy.Mombro` et al., while studying mothers in Turin, Italy using the
Lebech criteria,8 described the rate of transmission as being 4.1%
among possible and unlikely TP cases.24 Once again, these small
discrepancies can be attributed to rates of TP, which vary according
to geographic regions and the immune status of the study
population.
In the present study, the classiﬁcation of Lebech et al.8 was used
not only for its biological plausibility, but also for its easy
application. Still, 61.3% of mothers (n = 318/519) could not be
classiﬁed with regard to the probability of infection, due to
incompleteness of records for serological test results. These
ﬁndings indicate that health staff should be made aware of the
prenatal guidelines, in order to improve compliance with the
requisition and registration of serological testing. In addition, the
health sector must improve universal access to complementary
examinations to facilitate relevant diagnostic testing during
pregnancy.
Congenital transmission occurs only among women who have
acquired T. gondii during pregnancy (deﬁnite case), except in very
unusual situations. However, a large absolute number of CT cases
occurred among women listed as probable (n = 12), possible
(n = 9), and non-classiﬁed (n = 30) cases of TP. These ﬁndings
demonstrate difﬁculties in the diagnosis of acute TP and the loss of
opportunities for prenatal treatment. In addition, it was demon-
strated that among mothers who were considered unlikely cases of
TP (n = 25 mothers), no cases of CT were actually conﬁrmed. Still,
11 children born to this group of mothers went through laboratory
investigations and treatment right after birth, which were
probably unnecessary. These results raise the hypothesis of
uncertainty in the clinic management of presumed CT cases based,
sometimes, on unreliable classiﬁcations of maternal toxoplasmo-
sis.
In Brazil, the local and state guidelines for the clinical
management of a child born to a mother considered to be a case
of acute TP is based on positivity of IgM at any time during
pregnancy.7 However, there are no national guidelines concerning
CT. Moreover, there are no national or local guidelines for children
born to mothers listed as probable, possible, or unlikely cases of TP,
as proposed by Lebech et al.8 The lack of clinical guidelines leads to
individual medical decisions, based on different interpretations of
the probabilities of TP, which could result in delayed or
unnecessary diagnosis and treatment. To aid decision-making on
the clinical management of CT, the classiﬁcation of Lebech et al.,8
as modiﬁed by the authors, considers different serologic proﬁles
and not only the positivity of IgM; these may be useful in the
clinical management of children suspected of CT in developing
countries where prenatal screening may be unreliable.
As expected, in this study, the ‘deﬁnite’ category used for the
maternal classiﬁcation of TP was strongly predictive of CT: children
born to this group of mothers were 9.6 times more likely to be a
case of CT than those born to mothers listed as unlikely cases or
who were not listed. However, the predictive values of CT
considering the other three categories in the classiﬁcation of
Lebech et al.8 were not relevant. In future studies, other
classiﬁcations should be equally assessed for their predictive
capability of the probability of CT.
4.1. Prenatal treatment
A little over half of pregnant women were treated during the
prenatal period. However, prenatal treatment was identiﬁed in this
study as a protective factor for the occurrence of CT, especially
when started early on during pregnancy and continued up until
delivery. Children whose mothers were not given treatment were
three times more likely to be diagnosed with CT than those who
did, even adjusting for the classiﬁcation of probability of TP.
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did not receive prenatal treatment (n = 222) in our setting: (1) the
drugs were not available in the public health sector; (2) the doctor
considered that treatment was not indicated, especially in the
absence of a deﬁnitive diagnosis of TP; (3) the mother did not
comply with the treatment, even though it was prescribed by the
doctor, for several reasons including side effects.
The protective effect of prenatal treatment in preventing and/or
reducing the transmission of CT is controversial in the literature
worldwide. A multicenter European study showed no statistical
signiﬁcance for prenatal treatment and the prevention of the
transmission of CT in a multivariate analysis adjusted for the time
the infection occurred and the timing of the prenatal treatment.10
The authors, however, identiﬁed some important differences
between the groups being compared in the descriptive phase of
this study: a 39% transmission rate was reported among mothers
who were given prenatal treatment and a 72% transmission rate
was reported among untreated mothers (p > 0.05).10
In another study, Wallon et al.9 carried out a systematic review
that included nine studies involving women listed as deﬁnite or
presumed cases of TP, to assess the effect of prenatal treatment on
CT rates. Five of these studies showed that treatment was effective
in reducing the occurrence of CT while four others did not. Unlike
the present study, however, the authors did not consider the
regimen of drugs or the duration of treatment in the analysis. No
clinical trial (randomized or not) considering prenatal treatment
was identiﬁed in that review. The authors concluded that it
remains unclear whether prenatal treatment actually does reduce
the congenital transmission of T. gondii.
In this study, the transmission rate of CT among deﬁnite cases of
TP was 41.7% (n = 5/12) when treatment was given during the
prenatal period, in contrast to a transmission rate of 33.3% (n = 2/6)
when it was not. Studies were conducted in Lyon, France on a
group of 564 pregnant women who were infected with T. gondii
during pregnancy and who were treated,25 as well as in Saint
Etienne26 with a similar group of 79 pregnant women. Comparable
to our results (41.7%), the authors showed transmission rates of
29% and 35%, respectively. In Europe, a multicenter study in ﬁve
toxoplasmosis reference centers (in France, Belgium, Norway, and
Finland), investigated 144 pregnant women with the same
characteristics (pregnant, infected with T. gondii, and treated
prenatally), and described a transmission rate of 39%.10 The small
differences between the results related to CT rates in infected
pregnant women treated prenatally in the present study and those
reported in the literature may be related to the period of time in
which the acute infection occurred, the initiation of treatment, and
regional variations.
Regardless of the lack of deﬁnitive evidence on the impact of
prenatal treatment on CT rates in the reviewed literature, some
local guidelines7 and nationwide programs23,27 state that deﬁnite
cases of TP must be treated during pregnancy. On the other hand,
there are no recommendations regarding the treatment of
presumed cases of TP. As mentioned earlier, it is imperative to
conduct randomized and controlled clinical trials to assess the
effect of prenatal treatment on CT transmission rates, which may
generate high-quality evidence to help in clinical decision-making.
4.2. Drug regimens
The three prenatal treatment regimens analyzed by the authors
are the ones most commonly recommended in consensus
documents and guidelines drawn up by groups studying toxoplas-
mosis in different countries, such as: EMSCOT (European
Multicenter Study on Congenital Toxoplasmosis),28 the SYROCOT
(Systematic Review on Congenital Toxoplasmosis) study group,17
the Royal Institute of Public Health in the UK,16 the US Centers forDisease Control and Prevention (CDC) National Center for Infectious
Diseases,27 the Argentine Congress of Congenital Toxoplasmosis,23
and, in Brazil, from the Brazilian Network of Toxoplasmosis and State
Health Secretariat Parana´29 and the State Health Secretariat, FD.7
Furthermore, future publications from the Program of Toxoplasmo-
sis of the Ministry of Health in Brazil will include guidelines on
speciﬁc drug regimens (personal communication).
Regimen 1 was the most frequently used because of global and
national recommendations (mentioned above), which propose
the use of spiramycin until a fetal diagnosis is conﬁrmed. This
regimen is considered to be effective in eliminating T. gondii from
the placenta,14,16 has good compliance since it is based on only
one drug and causes fewer side-effects (in contrast to pyrimeth-
amine which may cause bone marrow aplasia), and is of lower cost
and greater availability in public health services. On the other
hand, the two other drug regimens are mainly prescribed if fetal
toxoplasmosis is conﬁrmed, since spiramycin does not cross the
placental barrier, which makes it ineffective for treatment of the
fetus.13,14,17,28,30
In the present study, there were no signiﬁcant differences in CT
transmission rates when regimens 2 and 3 were compared to
regimen 1. In the reviewed literature, only two French studies
associated transmission rates of CT to particular drug regimens. One
of them, by Gilbert et al.,11 found no difference in the transmission
rates among 544 infected pregnant women treated with spiramycin
or pyrimethamine combined with sulfadiazine in relation to
reducing transmission. Similarly, Kieffer et al.31 found no statistical
differences comparing these different treatments (as presented in
our study) to the rates of CT among the 1438 pregnant women.
Again, more deﬁnite scientiﬁc evidence should be accumulated,
preferably from randomized therapeutic trials, to evaluate the
effectiveness of the drug regimens in the prevention of CT.
4.3. Timing of treatment
The multivariate analysis conﬁrmed a higher transmission rate
of CT when treatment was started in the third trimester of
pregnancy in comparison to the ﬁrst trimester of pregnancy, even
after adjusting for the classiﬁcation of TP. In this study population,
it was not possible to differentiate the time of infection during
pregnancy from the timing of treatment initiation, since the time of
seroconversion was not identiﬁed. Therefore, this result may
conﬁrm the well-known higher transmission of T. gondii due to
high placental vascularization in the last trimester of pregnancy
and/or may reﬂect a delay of treatment if infection occurred earlier
during pregnancy. This analysis would be greatly enhanced if the
information about the trimester in which infection occurred was
available for association with the effect of prenatal treatment.
Wallon et al.9 agreed that the protective effect of treatment
becomes more evident when the infected pregnant woman is
treated during the ﬁrst trimester of pregnancy. Dunn et al.25
studied 603 pregnant women with toxoplasmosis conﬁrmed in the
laboratory in Lyon, France. The overall transmission rate was 29%,
rising considerably during the pregnancy up to 72% in the 36th
week (third trimester), even though these patients were given
treatment.
4.4. Duration of treatment
Among women who received treatment (n = 282), the majority
(n = 243, 86.2%) maintained it until delivery; this is affected by
access to medication, as well as awareness of the pregnant woman
of the need to comply with treatment in order to reduce the
chances of CT. Similarly, a study from the south of Brazil reported a
lower degree of uninterrupted treatment (57%) for 290 pregnant
women.32
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pregnancy) was a protective factor against CT (p = 0.001), probably
because it prevents the transmission of T. gondii in the last
trimesters of pregnancy when the placenta is more vascularized.
Couto et al.33 strongly recommend that spiramycin should be given
up until delivery. Once again, no studies analyzing the association
of continuous treatment and the occurrence of CT were found in
the reviewed literature.
4.5. Limitations
The limitations of this study are directly associated with
possible misclassiﬁcation of the mothers, associated with the
difﬁculty in estimating the likelihood of acute toxoplasmosis, as
well as conﬁrming seroconversion. Also, the limitations inherent to
observational studies when the aim is to evaluate therapeutic
effectiveness should be highlighted. Indication bias may occur
when the groups being compared (for example, treated groups
versus non-treated groups, and groups who were submitted to
different treatment regimens) become notably different, due to
medical indication. However, the proportion of treated mothers
varied little in relation to the classiﬁcation of TP, preventing the
occurrence of such a bias. For example, deﬁnite cases (63.1%) and
presumed cases (55.5%) had similar probability of being treated.
This may be due to the fact that, in Brazil, the decision to give
treatment and the choice in favor of therapeutic regimens is, at
times, strongly inﬂuenced by the positivity of IgM antibodies in the
pregnant woman and not by the classiﬁcation (Lebech et al.8) used
in this study. The adjustment of the analysis by the classiﬁcation of
the pregnant woman may have helped, in part, to control this
distortion.
4.6. Strengths
Based on the reviewed literature, both national and interna-
tional, this is the ﬁrst large group analytical study to clinically
evaluate the association between the occurrence of CT and
classiﬁcations of TP and prenatal treatment. Furthermore, the use
of a relevant sample (524 children) adds precision to the results
described. This study becomes even more relevant when the lack
of controlled therapeutic trials in the literature related to this
subject is considered. The results, especially the association
between the time and duration of prenatal treatment, as well as
the type, with the occurrence of CT, can greatly assist obstetricians
and pediatricians in the clinical management of children
suspected of toxoplasmosis in both the postnatal and prenatal
phases.
5. Conclusions
The classiﬁcation of Lebech et al.8 (modiﬁed by the authors)
showed a low predictive capability for describing the groups at
high risk for CT in detail, except for the deﬁnite cases of TP group.
This may be related to the great majority of pregnant women who
could not be classiﬁed.
Among deﬁnite cases of TP, there was an increased chance of CT
when prenatal treatment was not given. The protective effect of the
prenatal treatment was noticed especially when treatment was
given during the ﬁrst trimester of pregnancy and continued until
delivery. However, the regimen of drugs was not associated with
the rate of transmission of CT.
Our inability to list 61.3% of the pregnant women and to identify
the trimester of seroconversion, as well as the absence of treatment
in a large proportion of deﬁnite case of TP, reﬂect the need for
guidelines and improvements in order to provide higher quality
prenatal care, including universal access to essential laboratoryinvestigations and qualiﬁed professionals in the clinical manage-
ment of pregnant women.
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